azelastine has been researched along with Rhinitis in 14 studies
azelastine: azeptin is azelastine hydrochloride; structure; eye drop formulation effective in relieving symptoms of allergic conjunctivitis; do not confuse with 5-loxin which is an extract of Boswellia
azelastine : A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position.
Rhinitis: Inflammation of the NASAL MUCOSA, the mucous membrane lining the NASAL CAVITIES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We recruited 24 subjects with perennial allergic rhinitis and randomized them in a double-blinded, crossover fashion, to receive placebo or azelastine two sprays BID, using Balaam's design." | 9.09 | Effect of topical nasal azelastine on the symptoms of rhinitis, sleep, and daytime somnolence in perennial allergic rhinitis. ( Berlin, JM; Chinchilli, V; Craig, TJ; Golden, S; Kakumanu, S; Lehman, EB; Lucus, T; Mauger, EA; Teets, SJ, 2000) |
| "05% azelastine eye drops twice daily administered for 14 days to patients with seasonal allergic conjunctivitis or rhinoconjunctivitis." | 9.08 | Double-blind, randomised, placebo-controlled study of two concentrations of azelastine eye drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. ( Lenhard, G; Mivsek-Music, E; Obtulowicz, K; Perrin-Fayolle, M; Secchi, A, 1997) |
| "The study was carried out to investigate the effect of azelastine on the Substance P (SP) concentration in bronchoalveolar (BAL) and nasal (NAL) lavage obtained from atopic grass pollen asthmatics and non-atopic healthy subjects." | 9.07 | Effect of azelastine on substance P content in bronchoalveolar and nasal lavage fluids of patients with allergic asthma. ( Baumgarten, C; Furkert, J; Kunkel, G; Laake, E; Müller, S; Nieber, K; Rathsack, R, 1993) |
| "Azelastine is a potent H(1)-antihistamine, which is available as a topical nasal spray and indicated for both seasonal allergic and non-allergic vasomotor rhinitis." | 8.84 | Review of azelastine nasal spray in the treatment of allergic and non-allergic rhinitis. ( Corren, J; Lee, C, 2007) |
| "Azelastine hydrochloride (azelastine) nasal spray is a histamine receptor-1 (H1) antagonist often used in treating allergic rhinitis to relieve its symptoms." | 7.91 | Azelastine nasal spray inhibiting sympathetic function on human nasal mucosa in patients with allergy rhinitis. ( Cheng, LH; Chu, YH; Lee, JC; Lin, YY; Wang, HW; Wu, PC, 2019) |
| "Nonallergic rhinitis patients exhibited increased blood flow to several regions of the brain in response to both pleasant and unpleasant odorants, specifically in odor-sensitive regions, while off intranasal azelastine." | 7.77 | Alteration of brain activation patterns in nonallergic rhinitis patients using functional magnetic resonance imaging before and after treatment with intranasal azelastine. ( Allendorfer, JB; Bernstein, JA; Boespflug, EL; Eliassen, JC; Hastings, L; Lamy, M, 2011) |
| "To determine if greater efficacy could be achieved with the intranasal antihistamine azelastine and the intranasal corticosteroid fluticasone propionate used concurrently in the treatment of nasal obstruction of persistent non-allergic rhinitis." | 5.20 | [Clinical study of the combination therapy with intranasal antihistamine and nasal corticosteroids in the treatment of nasal obstruction of persistent non-allergic rhinitis]. ( Guo, L; Liu, J; Sun, X; Wang, D; Yang, J, 2015) |
| "We recruited 24 subjects with perennial allergic rhinitis and randomized them in a double-blinded, crossover fashion, to receive placebo or azelastine two sprays BID, using Balaam's design." | 5.09 | Effect of topical nasal azelastine on the symptoms of rhinitis, sleep, and daytime somnolence in perennial allergic rhinitis. ( Berlin, JM; Chinchilli, V; Craig, TJ; Golden, S; Kakumanu, S; Lehman, EB; Lucus, T; Mauger, EA; Teets, SJ, 2000) |
| "05% azelastine eye drops twice daily administered for 14 days to patients with seasonal allergic conjunctivitis or rhinoconjunctivitis." | 5.08 | Double-blind, randomised, placebo-controlled study of two concentrations of azelastine eye drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. ( Lenhard, G; Mivsek-Music, E; Obtulowicz, K; Perrin-Fayolle, M; Secchi, A, 1997) |
| "The study was carried out to investigate the effect of azelastine on the Substance P (SP) concentration in bronchoalveolar (BAL) and nasal (NAL) lavage obtained from atopic grass pollen asthmatics and non-atopic healthy subjects." | 5.07 | Effect of azelastine on substance P content in bronchoalveolar and nasal lavage fluids of patients with allergic asthma. ( Baumgarten, C; Furkert, J; Kunkel, G; Laake, E; Müller, S; Nieber, K; Rathsack, R, 1993) |
| "Azelastine is a potent H(1)-antihistamine, which is available as a topical nasal spray and indicated for both seasonal allergic and non-allergic vasomotor rhinitis." | 4.84 | Review of azelastine nasal spray in the treatment of allergic and non-allergic rhinitis. ( Corren, J; Lee, C, 2007) |
| "To review existing treatments for rhinitis and summarize data available on the use of a nasal antihistamine (azelastine) in treating allergic and nonallergic vasomotor rhinitis." | 4.84 | A novel and effective approach to treating rhinitis with nasal antihistamines. ( Kaliner, MA, 2007) |
| "Azelastine hydrochloride (azelastine) nasal spray is a histamine receptor-1 (H1) antagonist often used in treating allergic rhinitis to relieve its symptoms." | 3.91 | Azelastine nasal spray inhibiting sympathetic function on human nasal mucosa in patients with allergy rhinitis. ( Cheng, LH; Chu, YH; Lee, JC; Lin, YY; Wang, HW; Wu, PC, 2019) |
| "Nonallergic rhinitis patients exhibited increased blood flow to several regions of the brain in response to both pleasant and unpleasant odorants, specifically in odor-sensitive regions, while off intranasal azelastine." | 3.77 | Alteration of brain activation patterns in nonallergic rhinitis patients using functional magnetic resonance imaging before and after treatment with intranasal azelastine. ( Allendorfer, JB; Bernstein, JA; Boespflug, EL; Eliassen, JC; Hastings, L; Lamy, M, 2011) |
| "Rhinitis is a common condition that affects a significant proportion of the general population, as well as a high proportion of athletes." | 2.43 | Nasal obstruction, the airway, and the athlete. ( Craig, TJ; Davies, MJ; Fisher, LH, 2005) |
| "Nonallergic rhinitis is a common disease that probably affects as many as 17 million Americans." | 2.41 | Update on nonallergic rhinitis. ( Lieberman, P; Settipane, RA, 2001) |
| "Rhinosinusitis was assessed by questionnaires, direct examination of the nose and by high-resolution computed tomography." | 1.35 | Postnasal drip and chronic cough: An open interventional study. ( Arbery, J; Chung, KF; Durham, SR; Macedo, P; MacKay, I; Saleh, H; Torrego, A, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Procopiou, PA | 1 |
| Browning, C | 1 |
| Buckley, JM | 1 |
| Clark, KL | 1 |
| Fechner, L | 1 |
| Gore, PM | 1 |
| Hancock, AP | 1 |
| Hodgson, ST | 1 |
| Holmes, DS | 1 |
| Kranz, M | 1 |
| Looker, BE | 1 |
| Morriss, KM | 1 |
| Parton, DL | 1 |
| Russell, LJ | 1 |
| Slack, RJ | 1 |
| Sollis, SL | 1 |
| Vile, S | 1 |
| Watts, CJ | 1 |
| Cheng, LH | 1 |
| Lee, JC | 1 |
| Wu, PC | 1 |
| Lin, YY | 1 |
| Chu, YH | 1 |
| Wang, HW | 1 |
| Guo, L | 1 |
| Sun, X | 1 |
| Yang, J | 1 |
| Liu, J | 1 |
| Wang, D | 1 |
| Daramola, OO | 1 |
| Kern, RC | 1 |
| Macedo, P | 1 |
| Saleh, H | 1 |
| Torrego, A | 1 |
| Arbery, J | 1 |
| MacKay, I | 1 |
| Durham, SR | 1 |
| Chung, KF | 1 |
| Bernstein, JA | 1 |
| Hastings, L | 1 |
| Boespflug, EL | 1 |
| Allendorfer, JB | 1 |
| Lamy, M | 1 |
| Eliassen, JC | 1 |
| Fisher, LH | 1 |
| Davies, MJ | 1 |
| Craig, TJ | 2 |
| Lee, C | 1 |
| Corren, J | 1 |
| Kaliner, MA | 1 |
| Nieber, K | 1 |
| Baumgarten, C | 1 |
| Rathsack, R | 1 |
| Furkert, J | 1 |
| Laake, E | 1 |
| Müller, S | 1 |
| Kunkel, G | 1 |
| Lenhard, G | 1 |
| Mivsek-Music, E | 1 |
| Perrin-Fayolle, M | 1 |
| Obtulowicz, K | 1 |
| Secchi, A | 1 |
| Golden, S | 1 |
| Teets, SJ | 1 |
| Lehman, EB | 1 |
| Mauger, EA | 1 |
| Chinchilli, V | 1 |
| Berlin, JM | 1 |
| Kakumanu, S | 1 |
| Lucus, T | 1 |
| Stone, BD | 1 |
| Settipane, RA | 1 |
| Lieberman, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Role of the Nose for Physical Capacity[NCT04712799] | Phase 4 | 67 participants (Anticipated) | Interventional | 2021-01-13 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for azelastine and Rhinitis
| Article | Year |
|---|---|
An update regarding the treatment of nonallergic rhinitis.
Topics: Administration, Intranasal; Adrenal Cortex Hormones; Beclomethasone; Capsaicin; Drug Therapy, Combin | 2016 |
Nasal obstruction, the airway, and the athlete.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Asthma; Nasal Obstruction; Phthalazines; Respiratory System | 2005 |
Review of azelastine nasal spray in the treatment of allergic and non-allergic rhinitis.
Topics: Administration, Intranasal; Animals; Anti-Allergic Agents; Biological Availability; Humans; Phthalaz | 2007 |
A novel and effective approach to treating rhinitis with nasal antihistamines.
Topics: Administration, Intranasal; Adrenal Cortex Hormones; Drug Therapy, Combination; Histamine H1 Antagon | 2007 |
Update on nonallergic rhinitis.
Topics: Adrenal Cortex Hormones; Adult; Age of Onset; Air Pollution; Anti-Inflammatory Agents, Non-Steroidal | 2001 |
4 trials available for azelastine and Rhinitis
| Article | Year |
|---|---|
[Clinical study of the combination therapy with intranasal antihistamine and nasal corticosteroids in the treatment of nasal obstruction of persistent non-allergic rhinitis].
Topics: Administration, Intranasal; Adrenal Cortex Hormones; Drug Therapy, Combination; Histamine H1 Antagon | 2015 |
Effect of azelastine on substance P content in bronchoalveolar and nasal lavage fluids of patients with allergic asthma.
Topics: Adolescent; Adult; Asthma; Bronchoalveolar Lavage Fluid; Exudates and Transudates; Female; Histamine | 1993 |
Double-blind, randomised, placebo-controlled study of two concentrations of azelastine eye drops in seasonal allergic conjunctivitis or rhinoconjunctivitis.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Conjunctivitis, Allergic; Dermatitis, Irritant; Doubl | 1997 |
Effect of topical nasal azelastine on the symptoms of rhinitis, sleep, and daytime somnolence in perennial allergic rhinitis.
Topics: Administration, Topical; Adolescent; Adult; Circadian Rhythm; Cross-Over Studies; Double-Blind Metho | 2000 |
5 other studies available for azelastine and Rhinitis
| Article | Year |
|---|---|
The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.
Topics: Administration, Intranasal; Administration, Oral; Drug Discovery; Histamine H1 Antagonists; Histamin | 2011 |
Azelastine nasal spray inhibiting sympathetic function on human nasal mucosa in patients with allergy rhinitis.
Topics: Administration, Intranasal; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Humans; Na | 2019 |
Postnasal drip and chronic cough: An open interventional study.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Androstadienes; Anti-Inflammatory Agents, Non-S | 2009 |
Alteration of brain activation patterns in nonallergic rhinitis patients using functional magnetic resonance imaging before and after treatment with intranasal azelastine.
Topics: Administration, Intranasal; Adult; Brain; Female; Humans; Longitudinal Studies; Magnetic Resonance I | 2011 |
Studies of nasal sprays for rhinitis.
Topics: Administration, Intranasal; Bronchodilator Agents; Double-Blind Method; Humans; Phthalazines; Rhinit | 2000 |